2023年第四季度及全年产品收入(DAXXIFY®和RHA®系列)分别为5850万美元和2.127亿美元,同比增长约28%和80%。
- 第四季度DAXXIFY销量比2023年第三季度增长22%,四分之三的第四季度收入来自重复订购账户。
- 2024年产品收入指导至少为2.8亿美...查看全文
Revance疗法(RVNC)03-20 06:45
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000066 Size: 7 KB 网页链接查看全文
Revance疗法(RVNC)03-20 06:55
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000068 Size: 7 KB 网页链接查看全文
Revance疗法(RVNC)03-22 04:15
$Revance疗法(RVNC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001479290-24-000072 Act: 34 Size: 1 MB 网页链接查看全文
Revance疗法(RVNC)03-09 05:35
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000056 Size: 5 KB 网页链接查看全文
Revance疗法(RVNC)05-03 20:55
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000088 Size: 7 KB 网页链接查看全文
Revance疗法(RVNC)05-03 20:45
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000084 Size: 7 KB 网页链接查看全文
Revance疗法(RVNC)04-18 04:45
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000074 Size: 5 KB 网页链接查看全文
Revance疗法(RVNC)03-22 04:15
$Revance疗法(RVNC)$ DEF 14A Other definitive proxy statements Accession Number: 0001479290-24-000071 Act: 34 Size: 14 MB 网页链接查看全文
f77882021-05-26 22:16
$Revance疗法(RVNC)$ 0848 ET - Revance Therapeutics, which is awaiting FDA approval of its injection treatment for frown lines, says the agency plans to a launch its delayed pre-approval inspection of the company's manufacturing plant by the end of June. The FDA early last...查看全文
产业链观察2020-11-25 21:54
药闻| 2020年11月25日,专注于创新美学和治疗产品的生物技术公司$Revance疗法(RVNC)$ 报告其肉毒杆菌毒素A的生物制剂许可申请(BLA,用于治疗中至重度间质(皱眉)系)收到FDA推迟决定。
在2020年11月24日收到的信函中,FDA重申作为BLA批准程序的一部分,必须对公司的生产设施进行检查。由于该...查看全文
牛唐2019-05-17 12:10
$Revance疗法(RVNC)$ RT-002针对眉间线的药物计划6月底前递交NDA,之前的数据非常好,跟$复星医药(SH600196)$ 有合作,对标$Evolus(EOLS)$ ,估值还有不少空间;查看全文
chrisjiang20022018-12-05 12:24
复星医药的这一款肉毒杆菌是这么回事:参考大名鼎鼎的肉毒杆菌Botox是美国 $艾尔建医疗(AGN)$ 公司的看家产品,中老年女人和女明星们的至爱,去年销售额30亿美元,公司股价十年股价回报6倍。目前Botox迎来竞争对手,即 $Revance疗法(RVNC)$ 生产的Botox生物仿制药,已经赢得了与Botox头对头比较试...查看全文
$Revance疗法(RVNC)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001479290-24-000100 Act: 34 Size: 7 MB 网页链接
$Revance疗法(RVNC)$ 8-K Current report, items 2.02, 7.01, 8.01, and 9.01 Accession Number: 0001479290-24-000099 Act: 34 Size: 362 KB 网页链接
$Revance疗法(RVNC)$ 8-K Current report, item 5.07 Accession Number: 0001479290-24-000092 Act: 34 Size: 150 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000086 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000088 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000087 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000089 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000090 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000085 Size: 7 KB 网页链接
$Revance疗法(RVNC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001479290-24-000084 Size: 7 KB 网页链接